AI Science Tracker

AstraZeneca Centre for Genomics Research

1 discovery from 2024

Discoveries

MILTON-augmented disease cohorts surface putative new gene–disease associations in UK Biobank data

MILTON uses machine learning on routine clinical biomarkers, quantitative traits and plasma proteomics to predict disease phenotypes and augment case labels in UK Biobank. In a phenome-wide analysis of 484,230 genome-sequenced participants, the authors report 182 putative novel gene–disease associations that were not genome-wide significant in baseline cohorts or explained by biomarker associations; 38.9% of the 167 mappable signals were nominally supported with the same direction in FinnGen.

Technology: MILTON (Machine Learning with Phenotype Associations), an ensemble machine-learning framework for disease prediction from clinical and molecular biomarkers

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: In a phenome-wide analysis of 484,230 genome-sequenced participants, the authors report 182 putative novel gene–disease associations that were not genome-wide significant in baseline cohorts or explained by biomarker associations; 38.9% of the 167 mappable signals were nominally supported with the same direction in FinnGen.
  • Still unknown: The authors classify the 182 associations as putative novel; they are computational associations, not experimentally established causal genes. FinnGen nominal same-direction support applied to 38.92% (65/167) of the mappable putative novel PheWAS associations, while the paper also reports other aggregate exome-wide results. A separate example, APOB–thyrotoxicosis, showed FinnGen support. These signals require further biological validation.
  • AI role: MILTON predicted cases from clinical biomarkers and other quantitative traits, augmenting phenotype labels for genetic association analyses. The AI-enabled cohort enrichment yielded putative novel gene–disease signals; the study compared them with baseline analyses, orthogonal prioritization tools and FinnGen.

Evidence sources: https://www.nature.com/articles/s41588-024-01898-1.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 137 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.